20150291 (R/R)

20150291 (R/R)

A Phase 2 Open-Label Study to Determine the Effect of Blinatumomab on Minimal Residual Disease in Subjects with High-risk Diffuse Large B-cell Lymphoma (DLBCL) Post-autologous Hematopoietic Stem-cell Transplantation


Study Treatments


Inclusion criteria


Exclusion criteria


Participating sites


Link